Literature DB >> 7084806

Anti-LSP antibodies in acute liver disease.

R Meliconi, A Perperas, D Jensen, A Alberti, I G McFarlane, A L Eddleston, R Williams.   

Abstract

Sera from 71 patients with acute liver injury have been tested for antibodies to hepatocyte membrane lipoprotein complex (LSP) using a sensitive radioimmunoassay. Two main patterns of anti-LSP response were seen. In the first, seen in patients with type A and B viral hepatitis, anti-LSP antibodies were detectable at presentation, with the highest titres two to 10 days before the peak in serum aminotransferases and, in the hepatitis B patients, when viral DNA polymerase concentrations were still high, indicating active viral replication. These findings are consistent with the anti-LSP response being consequent on an interaction between T cells and neoantigens on the liver cell surface. A similar pattern was found in halothane hepatitis where immune responses to a halothane-altered liver membrane antigen are present early in the course of the disease. In the second type of response, exemplified by cases with paracetamol-induced hepatic necrosis, anti-LSP was only occasionally detectable at presentation, although present in very low titre later in the clinical course. This may be due to the release of altered antigen at the time of hepatocellular injury. The same pattern was found in a selected group of patients with uncomplicated acute alcoholic hepatitis, suggesting that in both these groups of patients the liver damage may have been due to a direct toxic effect on liver cells.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7084806      PMCID: PMC1419772          DOI: 10.1136/gut.23.7.603

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  18 in total

1.  Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo.

Authors:  D J Jollow; J R Mitchell; W Z Potter; D C Davis; J R Gillette; B B Brodie
Journal:  J Pharmacol Exp Ther       Date:  1973-10       Impact factor: 4.030

2.  T-lymphocyte cytotoxicity to HBsAg-coated target cells in hepatitis b virus infection.

Authors:  A Alberti; G Realdi; F Bortolotti; A M Rigoli
Journal:  Gut       Date:  1977-12       Impact factor: 23.059

3.  Liver cell surface localization of hepatitis B antigen and of immunoglobulins in acute and chronic hepatitis and in liver cirrhosis.

Authors:  A Alberti; G Realdi; F Tremolada; G P Spina
Journal:  Clin Exp Immunol       Date:  1976-09       Impact factor: 4.330

4.  Inadequate antibody response to hBAg or suppressor T-cell defect in development of active chronic hepatitis.

Authors:  A L Eddleston; R Williams
Journal:  Lancet       Date:  1974-12-28       Impact factor: 79.321

5.  Cell-mediated immune reactivity to hepatitis B surface antigen in liver diseases.

Authors:  M C de Moura; S J Vernace; F Paronetto
Journal:  Gastroenterology       Date:  1975-08       Impact factor: 22.682

6.  Lymphocyte stimulation in hepatitis B infections.

Authors:  M J Tong; A M Wallace; R L Peters; T B Reynolds
Journal:  N Engl J Med       Date:  1975-08-14       Impact factor: 91.245

7.  Liver-cell-membrane autoantibody specific for inflammatory liver diseases.

Authors:  U Tage-Jensen; W Arnold; O Dietrichson; F Hardt; U Hopf; K H Meyer Zum Büschenfelde; J O Nielsen
Journal:  Br Med J       Date:  1977-01-22

8.  DNA polymerase associated with human hepatitis B antigen.

Authors:  P M Kaplan; R L Greenman; J L Gerin; R H Purcell; W S Robinson
Journal:  J Virol       Date:  1973-11       Impact factor: 5.103

9.  Evidence for phasic sequences in nuclear HBcAg formation and cell membrane-directed flow of core particles in chronic hepatitis B.

Authors:  F Gudat; L Bianchi
Journal:  Gastroenterology       Date:  1977-11       Impact factor: 22.682

10.  Mutliple hepatitis viruses in multiple attacks of acute viral hepatitis.

Authors:  J W Mosley; A G Redeker; S M Feinstone; R H Purcell
Journal:  N Engl J Med       Date:  1977-01-13       Impact factor: 91.245

View more
  11 in total

1.  In-vitro cell-mediated cytotoxicity for autologous liver cells in chronic non-A, non-B hepatitis.

Authors:  M Mondelli; A Alberti; F Tremolada; R Williams; A L Eddleston; G Realdi
Journal:  Clin Exp Immunol       Date:  1986-01       Impact factor: 4.330

2.  Isolation and characterization of proteolipids from rat liver (LSP) and kidney (KSP).

Authors:  D Jüngst; J Blumenstingl; W H Caselmann
Journal:  Lipids       Date:  1988-05       Impact factor: 1.880

3.  Antibodies to liver membrane antigens in chronic active hepatitis (CAH). II. Specificity for autoimmune CAH.

Authors:  I H Frazer; I J Kronborg; I R Mackay
Journal:  Clin Exp Immunol       Date:  1983-10       Impact factor: 4.330

4.  Occurrence and significance of IgG liver membrane autoantibodies (LMA) in chronic liver diseases of different aetiology.

Authors:  R Meliconi; M V Stancari; M Garagnani; M Baraldini; G F Stefanini; F Miglio; G Gasbarrini
Journal:  Clin Exp Immunol       Date:  1983-03       Impact factor: 4.330

5.  Circulating hepatocyte membrane-specific autoantibodies in chronic active hepatitis type B. Relation to virus replication activity and liver cell necrosis.

Authors:  R Meliconi; M Baraldini; A Alberti; F Bortolotti; G Realdi; A Facchini; G Gasbarrini; G Labo
Journal:  Dig Dis Sci       Date:  1984-07       Impact factor: 3.199

6.  Liver abnormalities and liver membrane autoantibodies in systemic lupus erythematosus.

Authors:  K Kushimoto; K Nagasawa; A Ueda; T Mayumi; Y Ishii; Y Yamauchi; Y Tada; H Tsukamoto; T Kusaba; Y Niho
Journal:  Ann Rheum Dis       Date:  1989-11       Impact factor: 19.103

7.  Antibodies directed against human liver specific membrane lipoprotein (LSP) in marmosets experimentally infected with the hepatitis A virus.

Authors:  D M Jensen; D A Peterson; L G Wolfe; T Hurley; J A Payne; J Ogden
Journal:  Clin Exp Immunol       Date:  1984-03       Impact factor: 4.330

8.  Thymus-dependence of autoantibody responses to liver specific lipoprotein in the mouse.

Authors:  W N Bartholomaeus; H O'Donoghue; W D Reed
Journal:  Clin Exp Immunol       Date:  1984-03       Impact factor: 4.330

9.  Antibodies to liver cell membrane antigens in chronic active hepatitis (CAH). III. Partial characterization of the liver cell membrane antigens and comparison of reactivities in sera from patients with various liver diseases.

Authors:  I H Frazer; I R Mackay
Journal:  Clin Exp Immunol       Date:  1984-08       Impact factor: 4.330

10.  Autoantibody to liver-specific lipoprotein in the mouse: regulation by naturally occurring autoantigen specific suppressor cells.

Authors:  W N Bartholomaeus; W D Reed; R A Joske
Journal:  Clin Exp Immunol       Date:  1984-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.